Bugworks Research India Pvt. Ltd., Bengaluru, Karnataka, India.
Novartis Healthcare Pvt. Ltd., Hyderabad, Telangana, India.
Yale J Biol Med. 2024 Jun 28;97(2):179-204. doi: 10.59249/VTBV6559. eCollection 2024 Jun.
Aldo-keto reductases (AKRs) are a superfamily of promiscuous enzymes that have been chiseled by evolution to act as catalysts for numerous regulatory pathways in humans. However, they have not lost their promiscuity in the process, essentially making them a double-edged sword. The superfamily is involved in multiple metabolic pathways and are linked to chronic diseases such as cataracts, diabetes, and various cancers. Unlike other detoxifying enzymes such as cytochrome P450s (CYP450s), short-chain dehydrogenases (SDRs), and medium-chain dehydrogenases (MDRs), that participate in essential pathways, AKRs are more widely distributed and have members with interchangeable functions. Moreover, their promiscuity is ubiquitous across all species and participates in the resistance of pathogenic microbes. Moreover, the introduction of synthetic substrates, such as synthetic molecules and processed foods, results in unwanted "toxification" due to enzyme promiscuity, leading to chronic diseases.
醛酮还原酶(AKR)是一个多功能酶超家族,在进化过程中被雕琢成人类众多调控途径的催化剂。然而,在这个过程中,它们并没有失去多功能性,本质上使它们成为一把双刃剑。该超家族参与多种代谢途径,并与白内障、糖尿病和各种癌症等慢性疾病有关。与其他解毒酶(如细胞色素 P450 酶、短链脱氢酶和中链脱氢酶)不同,AKR 参与基本途径,其分布更为广泛,并且具有可互换功能的成员。此外,其多功能性在所有物种中普遍存在,并参与了致病微生物的耐药性。此外,由于酶的多功能性,合成底物(如合成分子和加工食品)的引入会导致不必要的“毒化”,从而导致慢性疾病。